December 1, 2017 Issue of JAMA Oncology

December 2017, Vol 3, No. 12, Pages 1599-1751

Original Investigation

Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis

Mandy L. Ballinger, PhD; Ana Best, PhD; Phuong L. Mai, MD; et al.

Abstract Full Text

free access

JAMA Oncol. 2017;3(12):1634-1639. doi:10.1001/jamaoncol.2017.1968

This meta-analysis assesses the clinical utility of whole-body magnetic resonance imaging in 13 cohorts of germline TP53 mutation carriers.

Invited Commentary
Cancer Screening in Li-Fraumeni Syndrome
Peter H. Asdahl, MD, PhD; Rohit P. Ojha, DrPH; Henrik Hasle, MD, PhD

JAMA Oncol

Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort

Phuong L. Mai; Payal P. Khincha, MD; Jennifer T. Loud; et al.

Abstract Full Text

free access has audio

JAMA Oncol. 2017;3(12):1640-1645. doi:10.1001/jamaoncol.2017.1350

This cohort study evaluates baseline surveillance methods for cancer detection in patients with Li-Fraumeni syndrome.

Podcast: Prevalence of Cancer in Li-Fraumeni Syndrome Cohort

Invited Commentary
Cancer Screening in Li-Fraumeni Syndrome
Peter H. Asdahl, MD, PhD; Rohit P. Ojha, DrPH; Henrik Hasle, MD, PhD

JAMA Oncol

Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women

Tom Walsh, PhD; Jessica B. Mandell, MS, CGC; Barbara M. Norquist, MD; et al.

Abstract Full Text

free access has audio

JAMA Oncol. 2017;3(12):1647-1653. doi:10.1001/jamaoncol.2017.1996

This cohort study uses genomic DNA from the New York Breast Cancer Study to determine the frequency of cancer-predisposing mutations other than the BRCA1 and BRCA2 founder alleles among patients of Ashkenazi Jewish ancestry with breast cancer.

Podcast: Breast Cancer Due to Non鈥揃RCA1 and Non鈥揃RCA2 Mutations in Ashkenazi Jewish Women

Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas

Dezheng Huo, MD, PhD; Hai Hu, PhD; Suhn K. Rhie, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2017;3(12):1654-1662. doi:10.1001/jamaoncol.2017.0595

This cohort study from The Cancer Genome Atlas investigates racial differences in breast cancer molecular features and survival and estimates the heritability of breast cancer subtypes.

Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy

Shuang G. Zhao, MD; S. Laura Chang, PhD; Nicholas Erho, MS; et al.

Abstract Full Text

free access

JAMA Oncol. 2017;3(12):1663-1672. doi:10.1001/jamaoncol.2017.0751

This study identifies prostate cancer subtypes based on luminal and basal lineage and assesses the association of those subtypes with clinical outcomes and response to treatment.

Invited Commentary
Prognostic and Predictive Value of a Breast Cancer Expression Signature in Localized Prostate Cancer
Wassim Abida, MD, PhD; Howard I. Scher, MD

JAMA Oncol

Development and Validation of a Novel Acute Myeloid Leukemia鈥揅omposite Model to Estimate Risks of Mortality

Mohamed L. Sorror, MD, MSc; Barry E. Storer, PhD; Amir T. Fathi, MD; et al.

Abstract Full Text

open access

JAMA Oncol. 2017;3(12):1675-1682. doi:10.1001/jamaoncol.2017.2714

This cohort study examines the prognostic association of comorbidities on 1-year mortality after initial therapy of acute myeloid leukemia and a risk-stratifying composite model that incorporates comorbidities, age, and cytogenetic/molecular risks.

The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015

Global Burden of Disease Liver Cancer Collaboration

Abstract Full Text

open access

JAMA Oncol. 2017;3(12):1683-1691. doi:10.1001/jamaoncol.2017.3055

This data analysis of the Global Burden of Disease 2015 study on primary liver cancer reports incidence, mortality, and disability-adjusted life-years for 195 countries or territories from 1990 to 2015, and presents global, regional, and national estimates on the burden of liver cancer.

Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio

Kyongsun Pak, BPharm; Hajime Uno, PhD; Dae Hyun Kim, MD; et al.

Abstract Full Text

free access

JAMA Oncol. 2017;3(12):1692-1696. doi:10.1001/jamaoncol.2017.2797

This comparative clinical study discusses problems with conventional trial design and analysis and presents alternatives to the hazard ratio using a recent immunotherapy study as an illustrative example.

Association of Systemic Inflammation and Sarcopenia With Survival in Nonmetastatic Colorectal Cancer: Results From the C SCANS Study

Elizabeth M. Cespedes Feliciano, ScD, MSc; Candyce H. Kroenke, ScD, MPH; Jeffrey A. Meyerhardt, MD, MPH; et al.

Abstract Full Text

free access online only

JAMA Oncol. 2017;3(12):e172319. doi:10.1001/jamaoncol.2017.2319

This cohort study of patients with early-stage colorectal cancer examines whether prediagnostic systemic inflammation is associated with at-diagnosis sarcopenia and explores whether these factors interact to predict cancer survival.

Dose-Response Association of CD8⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Ovarian Tumor Tissue Analysis (OTTA) Consortium

Abstract Full Text

free access online only

JAMA Oncol. 2017;3(12):e173290. doi:10.1001/jamaoncol.2017.3290

This cohort study examines the prognostic role of CD8⁺ T lymphocytes for survival among women with epithelial ovarian cancer.

Brief Report

Cancer Risk in Families Fulfilling the Amsterdam Criteria for Lynch Syndrome

N. Jewel Samadder, MD, MSc; Ken Robert Smith, PhD; Jathine Wong, BS; et al.

Abstract Full Text

free access

JAMA Oncol. 2017;3(12):1697-1701. doi:10.1001/jamaoncol.2017.0769

This population-based study evaluates the risk of cancer in families who are positive for Amsterdam criteria for Lynch syndrome.

Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies

Neil A. J. Ryan, MBChB; Julie Morris, MSc; Kate Green, MPhil; et al.

Abstract Full Text

open access

JAMA Oncol. 2017;3(12):1702-1706. doi:10.1001/jamaoncol.2017.0619

In this cohort study of patients with Lynch syndrome with colorectal, endometrial, and/or ovarian cancer, mutation genes and types are evaluated for their association with age at cancer onset.

Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer

Thomas Karn, PhD; Tingting Jiang, PhD; Christos Hatzis, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2017;3(12):1707-1711. doi:10.1001/jamaoncol.2017.2140

This study examines the association between genomic metrics and the extent of immune infiltration in triple-negative breast cancers.

Research Letter

Surveillance of Dutch Patients With Li-Fraumeni Syndrome: The LiFe-Guard Study

Marielle W. G. Ruijs, MD, PhD; Claudette E. Loo, MD, PhD; Colette A. J. M. van Buchem, MD; et al.

Abstract Full Text

free access

JAMA Oncol. 2017;3(12):1733-1734. doi:10.1001/jamaoncol.2017.1346

This cohort study of patients with Li-Fraumeni syndrome assesses the diagnostic yield and false-positive rate of an annual surveillance program including whole-body magnetic resonance imaging in patients identified as carriers of TP53 gene mutations.

Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging

Mandy L. Ballinger, PhD; Nicholas J. Ferris, FRANZCR; Kate Moodie, FRANZCR; et al.

Abstract Full Text

free access

JAMA Oncol. 2017;3(12):1735-1736. doi:10.1001/jamaoncol.2017.1355

This prospective study of surveillance strategies uses a whole-body screening program, including whole-body magnetic resonance imaging, in carriers of germline mutations in TP53.

Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial

Olivier Caron, MD; Thierry Frebourg, MD, PhD; Patrick R. Benusiglio, MD, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2017;3(12):1736-1737. doi:10.1001/jamaoncol.2017.1358

This interim analysis of an ongoing randomized clinical trial presents preliminary findings regarding use of whole-body magnetic resonance imaging for cancer surveillance of TP53 mutation carriers.

Review

Using the National Cancer Database for Outcomes Research: A Review

Daniel J. Boffa, MD; Joshua E. Rosen, BASc; Katherine Mallin, PhD; et al.

Abstract Full Text

JAMA Oncol. 2017;3(12):1722-1728. doi:10.1001/jamaoncol.2016.6905

This review describes the use of the National Cancer Database to study cancer care, with a focus on the advantages of using the database and important considerations that affect the interpretation of National Cancer Database studies.

JAMA Oncology Diagnostic Test Interpretation

A New Monoclonal Protein Detected in a Patient With Myeloma Undergoing Elotuzumab Therapy

Felicia Tang; Christine Schmotzer, MD; Rose C. Beck, MD, PhD

Abstract Full Text

JAMA Oncol. 2017;3(12):1729-1730. doi:10.1001/jamaoncol.2017.2665

This Diagnostic Test Interpretation examines serum protein electrophoresis and free light chain assay results in a patient with myeloma.

Viewpoint

Conflict of Interest, Conflicting Interests, and Effective Collaboration Between Academia and Industry on Preclinical and Clinical Cancer Research

Mace L. Rothenberg, MD; David H. Johnson, MD

Abstract Full Text

JAMA Oncol. 2017;3(12):1621-1622. doi:10.1001/jamaoncol.2017.1822

This Viewpoint examines several dimensions of conflicts of interest, describes the distinct entity of conflicting interests, and describes how they may affect clinical cancer research.

Declining Incidence Rates of Prostate Cancer in the United States: Is This Good News or Not?

Mary K. Downer, SM; Meir J. Stampfer, MD, DrPH; Matthew R. Cooperberg, MD, MPH

Abstract Full Text

JAMA Oncol. 2017;3(12):1623-1624. doi:10.1001/jamaoncol.2017.0470

This Viewpoint reports that prostate-specific antigen screening should be offered at a young age, and when potentially lethal cancers are more likely to be cured.

Editorial